|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
0.51/0.17
|
企業價值
231.49M
|
資產負債 |
每股賬面淨值
0.35
|
現金流量 |
現金流量率
0.34
|
損益表 |
收益
409.92M
|
每股收益
3.60
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/09/21 03:35 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment. |